Furthermore, cross-matching maternal serum with paternal platelets showed strong positive reactions against glycoprotein IIb-IIIa and Ib-IX complexes, and class 1 HLA. After further sample processing, ...

The antithrombotic efficacy of the monoclonal antibodies 6B4-Fab and MA-16N7C2 against platelet glycoprotein (GP) Ib and GP IIb/IIIa, respectively, on acute platelet-mediated thrombosis was evaluated ...

Methods We collected serum samples from 74 patients with SLE (≥ 4 American College of Rheumatology 1982 criteria) during high (H) and lower (L) SLE Disease activity index 2000 (SLEDAI-2K) score ...

Patients with resected, EGFR -mutated, stage IB to IIIA non–small cell lung cancer (NSCLC) treated with adjuvant osimertinib (Tagrisso) experienced a statistically significant and clinically ...

The phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in ...

RUC-4 (CeleCor Therapeutics), an investigational glycoprotein IIb/IIIa inhibitor (GPI) administered by subcutaneous injection, provides rapid and powerful platelet inhibition in patients with STEMI, ...

Reductions in ischemia complications achieved with cangrelor in patients undergoing PCI are maintained regardless of whether glycoprotein IIb/IIIa inhibitors were administered, according to recent ...

Medicure announced it has received FDA approval for a premixed bolus dose of its glycoprotein IIb/IIIa inhibitor tirofiban HCI for use in patients with non-ST segment elevation ACS. According to a ...

Teva announced the launch of Eptifibatide Injection, the generic version of Merck ‘s Integrilin. Integrilin is a GP IIb/IIIa blocker antiplatelet indicated for acute coronary syndrome, including ...

Adult patients with completely resected, early-stage NSCLC were eligible if they had pathologically confirmed stage IB to IIIA (microscopic N2 only) disease by the American Joint Committee on Cancer ...